NASHVILLE, Tenn. / Jul 26, 2023 / Business Wire / Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the second quarter ended June 30, 2023, on Wednesday, August 9, 2023, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update.
Conference Call Details: | ||||
Date: | Wednesday, August 9, 2023 | |||
Time: | 4:45 p.m. Eastern time | |||
Participant Dial-in: | 1-833-953-2434 (U.S.) | |||
Replay Dial-in (Passcode 3750229): | 1-877-344-7529 (U.S.) | |||
Webcast: (online replay through August 9, 2024) | ||||
About Harrow
Harrow Health, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year. For more information about Harrow, please visit harrow.com.
| Last Trade: | US$23.99 |
| Daily Change: | 0.64 2.74 |
| Daily Volume: | 197,107 |
| Market Cap: | US$854.280M |
March 24, 2025 March 17, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
